[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Passage Bio Inc (PASG)

Passage Bio Inc (PASG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,088
  • Shares Outstanding, K 3,208
  • Annual Sales, $ 0 K
  • Annual Income, $ -45,520 K
  • EBIT $ -49 M
  • EBITDA $ -48 M
  • 60-Month Beta 1.38
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.70

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-2.14
  • Number of Estimates 2
  • High Estimate $-1.45
  • Low Estimate $-2.84
  • Prior Year $-5.00
  • Growth Rate Est. (year over year) +57.20%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.93 +6.99%
on 05/08/26
12.05 -65.06%
on 04/17/26
-5.08 (-54.68%)
since 04/08/26
3-Month
3.93 +6.99%
on 05/08/26
12.05 -65.06%
on 04/17/26
-5.30 (-55.73%)
since 02/06/26
52-Week
3.93 +6.99%
on 05/08/26
20.00 -78.95%
on 01/09/26
-2.72 (-39.27%)
since 05/08/25

Most Recent Stories

More News
Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates

PBFT02 administration resulted in improvements in two disease progression biomarkers, as compared to natural history, reducing brain atrophy and stabilizing plasma NfL levels  FDA feedback from recent...

PASG : 4.21 (+3.19%)
Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights

Enrolled first three FTD-GRN patients in Cohort 3 of ongoing upliFT-D study Treated first FTD-C9orf72 patient with Dose 2 PBFT02 in Cohort 4 of upliFT-D study On track to report updated interim...

PASG : 4.21 (+3.19%)
Passage Bio to Participate in Upcoming Investor Conferences

PHILADELPHIA, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases,...

PASG : 4.21 (+3.19%)
Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights

Actively enrolling Cohort 3 (FTD-GRN) and Cohort 4 (FTD-C9orf72) patients in ongoing upliFT-D study Aligned with the U.S. Food and Drug Administration (FDA) on an analytical approach to establish...

PASG : 4.21 (+3.19%)
Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference

PHILADELPHIA, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases,...

PASG : 4.21 (+3.19%)
Passage Bio to Participate in Chardan’s 9th Annual Genetic Medicines Conference

PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases,...

PASG : 4.21 (+3.19%)
Passage Bio to Participate in H.C. Wainwright 27th Annual Global Investment Conference

PHILADELPHIA, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases,...

PASG : 4.21 (+3.19%)
Passage Bio Announces 1-for-20 Reverse Stock Split

PASG : 4.21 (+3.19%)
Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update

PASG : 4.21 (+3.19%)
Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights

PASG : 4.21 (+3.19%)

Business Summary

Passage Bio Inc. is a genetic medicines company. It is focused on developing transformative therapies for rare, monogenic central nervous system diseases. The company's principal product includes GM1 gangliosidosis, frontotemporal dementia and Krabbe disease which is in clinical stage. Passage Bio Inc....

See More

Key Turning Points

3rd Resistance Point 4.66
2nd Resistance Point 4.46
1st Resistance Point 4.34
Last Price 4.21
1st Support Level 4.01
2nd Support Level 3.81
3rd Support Level 3.68

See More

52-Week High 20.00
Fibonacci 61.8% 13.86
Fibonacci 50% 11.97
Fibonacci 38.2% 10.07
Last Price 4.21
52-Week Low 3.93

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.